Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations

Adam B. Cochrane; Haifa Lyster; Jo Ann Lindenfeld; Christina Doligalski; David Baran; Colleen Yost; Michael Shullo; Martin Schweiger; David Weill; Linda Stuckey; Steven Ivulich; Janet Scheel; Lisa Peters; Monica Colvin; Kyle Dawson; Reda Girgis; Phillip Weeks; Tracy Tse; Stuart Russell; Maureen Flattery; Doug Jennings; Michelle Kittleson; Tara Miller; Tam Khuu; Tamara Claridge; Patricia Uber; Katrina Ford; Christopher R. Ensor; Kathleen Simpson; Anne Dipchand; Robert L. Page

doi:10.1016/j.healun.2020.06.024

Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations

Adam B. Cochrane, Haifa Lyster, Jo Ann Lindenfeld, Christina Doligalski, David Baran, Colleen Yost, Michael Shullo, Martin Schweiger, David Weill, Linda Stuckey, Steven Ivulich, Janet Scheel, Lisa Peters, Monica Colvin, Kyle Dawson, Reda Girgis, Phillip Weeks, Tracy Tse, Stuart Russell, Maureen FlatteryDoug Jennings, Michelle Kittleson, Tara Miller, Tam Khuu, Tamara Claridge, Patricia Uber, Katrina Ford, Christopher R. Ensor, Kathleen Simpson, Anne Dipchand, Robert L. Page

Pediatrics Cardiology

Research output: Contribution to journal › Editorial

Abstract

In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation.

Original language	English
Pages (from-to)	1050-1069
Number of pages	20
Journal	Journal of Heart and Lung Transplantation
Volume	39
Issue number	10
DOIs	https://doi.org/10.1016/j.healun.2020.06.024
State	Published - Oct 2020

Keywords

generic immunosuppression
heart transplantation
immunosuppression
lung transplantation
pediatric transplantation

Access to Document

10.1016/j.healun.2020.06.024

Fingerprint Dive into the research topics of 'Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations'. Together they form a unique fingerprint.

Cite this

Cochrane, A. B., Lyster, H., Lindenfeld, J. A., Doligalski, C., Baran, D., Yost, C., Shullo, M., Schweiger, M., Weill, D., Stuckey, L., Ivulich, S., Scheel, J., Peters, L., Colvin, M., Dawson, K., Girgis, R., Weeks, P., Tse, T., Russell, S., ... Page, R. L. (2020). Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. Journal of Heart and Lung Transplantation, 39(10), 1050-1069. https://doi.org/10.1016/j.healun.2020.06.024

Cochrane, Adam B. ; Lyster, Haifa ; Lindenfeld, Jo Ann ; Doligalski, Christina ; Baran, David ; Yost, Colleen ; Shullo, Michael ; Schweiger, Martin ; Weill, David ; Stuckey, Linda ; Ivulich, Steven ; Scheel, Janet ; Peters, Lisa ; Colvin, Monica ; Dawson, Kyle ; Girgis, Reda ; Weeks, Phillip ; Tse, Tracy ; Russell, Stuart ; Flattery, Maureen ; Jennings, Doug ; Kittleson, Michelle ; Miller, Tara ; Khuu, Tam ; Claridge, Tamara ; Uber, Patricia ; Ford, Katrina ; Ensor, Christopher R. ; Simpson, Kathleen ; Dipchand, Anne ; Page, Robert L. / Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation : Access, formulations, generics, therapeutic drug monitoring, and special populations. In: Journal of Heart and Lung Transplantation. 2020 ; Vol. 39, No. 10. pp. 1050-1069.

@article{d80a54e4ceee4694afab54ded11efac0,

title = "Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations",

abstract = "In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation.",

keywords = "generic immunosuppression, heart transplantation, immunosuppression, lung transplantation, pediatric transplantation",

author = "Cochrane, {Adam B.} and Haifa Lyster and Lindenfeld, {Jo Ann} and Christina Doligalski and David Baran and Colleen Yost and Michael Shullo and Martin Schweiger and David Weill and Linda Stuckey and Steven Ivulich and Janet Scheel and Lisa Peters and Monica Colvin and Kyle Dawson and Reda Girgis and Phillip Weeks and Tracy Tse and Stuart Russell and Maureen Flattery and Doug Jennings and Michelle Kittleson and Tara Miller and Tam Khuu and Tamara Claridge and Patricia Uber and Katrina Ford and Ensor, {Christopher R.} and Kathleen Simpson and Anne Dipchand and Page, {Robert L.}",

year = "2020",

month = oct,

doi = "10.1016/j.healun.2020.06.024",

language = "English",

volume = "39",

pages = "1050--1069",

journal = "Journal of Heart and Lung Transplantation",

issn = "1053-2498",

number = "10",

}

Cochrane, AB, Lyster, H, Lindenfeld, JA, Doligalski, C, Baran, D, Yost, C, Shullo, M, Schweiger, M, Weill, D, Stuckey, L, Ivulich, S, Scheel, J, Peters, L, Colvin, M, Dawson, K, Girgis, R, Weeks, P, Tse, T, Russell, S, Flattery, M, Jennings, D, Kittleson, M, Miller, T, Khuu, T, Claridge, T, Uber, P, Ford, K, Ensor, CR, Simpson, K, Dipchand, A & Page, RL 2020, 'Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations', Journal of Heart and Lung Transplantation, vol. 39, no. 10, pp. 1050-1069. https://doi.org/10.1016/j.healun.2020.06.024

Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation : Access, formulations, generics, therapeutic drug monitoring, and special populations. / Cochrane, Adam B.; Lyster, Haifa; Lindenfeld, Jo Ann; Doligalski, Christina; Baran, David; Yost, Colleen; Shullo, Michael; Schweiger, Martin; Weill, David; Stuckey, Linda; Ivulich, Steven; Scheel, Janet; Peters, Lisa; Colvin, Monica; Dawson, Kyle; Girgis, Reda; Weeks, Phillip; Tse, Tracy; Russell, Stuart; Flattery, Maureen; Jennings, Doug; Kittleson, Michelle; Miller, Tara; Khuu, Tam; Claridge, Tamara; Uber, Patricia; Ford, Katrina; Ensor, Christopher R.; Simpson, Kathleen; Dipchand, Anne; Page, Robert L.

In: Journal of Heart and Lung Transplantation, Vol. 39, No. 10, 10.2020, p. 1050-1069.

Research output: Contribution to journal › Editorial

TY - JOUR

T1 - Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation

T2 - Access, formulations, generics, therapeutic drug monitoring, and special populations

AU - Cochrane, Adam B.

AU - Lyster, Haifa

AU - Lindenfeld, Jo Ann

AU - Doligalski, Christina

AU - Baran, David

AU - Yost, Colleen

AU - Shullo, Michael

AU - Schweiger, Martin

AU - Weill, David

AU - Stuckey, Linda

AU - Ivulich, Steven

AU - Scheel, Janet

AU - Peters, Lisa

AU - Colvin, Monica

AU - Dawson, Kyle

AU - Girgis, Reda

AU - Weeks, Phillip

AU - Tse, Tracy

AU - Russell, Stuart

AU - Flattery, Maureen

AU - Jennings, Doug

AU - Kittleson, Michelle

AU - Miller, Tara

AU - Khuu, Tam

AU - Claridge, Tamara

AU - Uber, Patricia

AU - Ford, Katrina

AU - Ensor, Christopher R.

AU - Simpson, Kathleen

AU - Dipchand, Anne

AU - Page, Robert L.

PY - 2020/10

Y1 - 2020/10

N2 - In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation.

AB - In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation.

KW - generic immunosuppression

KW - heart transplantation

KW - immunosuppression

KW - lung transplantation

KW - pediatric transplantation

UR - http://www.scopus.com/inward/record.url?scp=85090057022&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2020.06.024

DO - 10.1016/j.healun.2020.06.024

M3 - Editorial

C2 - 32883559

AN - SCOPUS:85090057022

VL - 39

SP - 1050

EP - 1069

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 10

ER -

Cochrane AB, Lyster H, Lindenfeld JA, Doligalski C, Baran D, Yost C et al. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. Journal of Heart and Lung Transplantation. 2020 Oct;39(10):1050-1069. https://doi.org/10.1016/j.healun.2020.06.024